Alphamab's M1231 ADC Begins Clinical Trial for Metastatic Cancers
Alphamab Oncology has initiated a clinical trial for a novel bispecific antibody drug conjugate (ADC), M1231, in Texas and Toronto. This is the second antibody from the lab to enter testing, following a COVID-19 medication. The trial, NCT04695847, focuses on safety for patients with metastatic solid tumors, esophageal cancer, and non-small cell lung cancer.
The medication's development spanned over two decades, starting with Dr. Lars Toleikis' doctoral thesis. It utilizes a human antibody invention from the Technical University of Brunswick, discovered by Professor Stefan Dübel's team. The ADC targets tumor cells specifically and inhibits growth, while also activating the body's immune system against the tumor. It aims to improve targeting and combat functions compared to existing antibody-based tumor drugs. The first patients with advanced tumors in the USA are now being clinically tested.
The clinical trial is expected to run until July 2023. It aims to investigate the safety of the drug for patients with the mentioned cancer types.
Alphamab Oncology's M1231, a bispecific antibody drug conjugate, is now in clinical testing. This 20-year development journey, involving an 'evolution in a test tube' using antibody-phage display, could lead to improved tumor targeting and combat functions. The trial's results, expected by July 2023, will provide insights into the drug's safety for patients with advanced tumors.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
